Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

C Ohyama, T Kojima, T Kondo, Y Naya, T Inoue… - International Journal of …, 2019 - Springer
Background Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …
被引用次数：24 相关文章

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses …

C Ohyama, T Kojima, T Kondo, Y Naya… - … Journal of Clinical …, 2019 - europepmc.org
Background Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses …

C Ohyama, T Kojima, T Kondo, Y Naya… - … Journal of Clinical …, 2019 - search.ebscohost.com
Background: Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …

[引用][C] Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population …

C Ohyama, T Kojima, T Kondo, Y Naya… - International Journal of …, 2019 - cir.nii.ac.jp
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma:
CheckMate 275 2-year global and Japanese patient population analyses | CiNii Research …

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

C Ohyama, T Kojima, T Kondo… - … journal of clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

C Ohyama, T Kojima, T Kondo… - … Journal of Clinical …, 2019 - kyushu-u.elsevierpure.com
Background: Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

C Ohyama, T Kojima, T Kondo, Y Naya… - … Journal of Clinical …, 2019 - search.proquest.com
Background Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

C Ohyama, T Kojima, T Kondo, Y Naya… - International Journal of …, 2019 - inis.iaea.org
Background Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

C Ohyama, T Kojima, T Kondo… - International …, 2019 - mdanderson.elsevierpure.com
Background: Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …